matthias

matthias Updated 

For full disclosure I've been a long time holder of MLI. I love this company for its fundamental strength: They are a market leading, cost-advantaged provider of copper and brass tubing, fittings, and valves for the construction and HVACR markets. The company repaid all its long-term debt a couple of years ago, and has diligently expanded and upgraded its...

matthias Updated 

Going into Labor Day weekend I like to have a little short. TSLA has outperformed over the 2-yr, 1-yr, and 6-mo time frames, but has under-performed more recently. The upswing over the last 10 days may prove to be a counter-trend move in the context of the downtrend. There are a number of related harmonic patterns that are suggesting as much. Beyond that, I...

matthias

The Supreme Court has asked the Biden administration to comment on the RoundUp weed killer case before it. Bayer execs see this as an indication that the court is taking an interest in it, and appear hopeful that the glyphosate litigation can finally be put to rest without adding to the already staggering cost to the company. The 2018 acquisition of Monsanto,...

matthias

I am long Aegon (AEG), having first bought it in 11/2020, and adding to it in 6/2021. AEG was, and remains, a turnaround play. Aegon is a European insurer, headquartered in the Netherlands, that also operates in the US through its TransAmerica subsidiary. European financials tend to trade at lower price-to-tangible-book-value multiples than their US peers, but...

matthias Updated 

UPLD just ended the week with a tiny gain. This would not be noteworthy, except that coming into this week, UPLD was down for a staggering 11 (!) consecutive weeks. The stock peaked in April this year, just underneath its ATH and subsequently drifted down. Once it fell below its VWAP-since-IPO level and couldn't regain that level, the dismal streak got started....

matthias Updated 

I think YNDX presents an attractive entry at its current price. The stock has been trending upward since late 2016 (see regression channel). Yesterday, amid broader weakness in Russian names following the US-Russian dispute over alleged gas attacks by the Syrian army, YNDX dropped from the middle of its regression channel all the way out. Today that weakness...

matthias Updated 

Bluebird has been a strong performer over the past year, which is now testing support. It probed its rising trendline support yesterday, and today dropped below that and tested its 100-day SMA. It seems that valuation concerns are the reason that the selling got underway a couple of days ago. But I haven't read anything negative about the strength of their...

matthias Updated 

QURE has been an extraordinarily strong performer since summer of last year, quintupling to $26+ a couple of weeks ago. The stock has since dropped a quick 20%. I plan to watch this tomorrow, and to buy on strength. My ultimate price target would be around $24, although I'd take first profit sooner. I like the fact that the company has a fair amount of cash in the...

matthias Updated 

Small development-stage biotech with ample cash and a partnership with Sanofi. Heart disease focus with initial compound entering Phase 3 trials. No immediate catalysts, but looks like a decent technical setup. Momentum leader that has quadrupled over the past year, currently in a meaningful pullback. Ideally would like to see it test the Feb lows and rising...

matthias Updated 

After a beat and raise on the 1/31 earnings report it popped initially, but then gradually gave it all up and dropped back to the $25/$26 consolidation level that first came into play in 9/17 following an impressive run. I think that valuation (fwd PE < 10) and the relatively long consolidation phase provide ample support at this level. This is not a fast mover,...